glp 1 name brands Market Overview: GLP-1 Agonists and the Obesity Market | Blog GLP-1 Receptor Agonist Shortage: Challenges

Nausea is common after starting these medications, but this generally ameliorates after 1-2 weeks of therapy

Alcohol use disorder (AUD) is the third-leading cause of preventable death in the United States, yet there are only three modestly effective drugs for treatment, the last one approved in 2006

Trulicity may work well for patients who need reliable blood sugar control without dramatic weight changes

In some trials, up to 2540% of total weight lost was lean mass, not fat

Across multiple STEP trials, the enrollment criteria required a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity (excluding type 2 diabetes, which was studied separately)